ArticleBMC cancer2019

Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.

Eric C Kauffman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.